December 26, 2022
Japan’s health ministry approved a throng of new medicines and indications on December 23 including Sanofi’s PD-1 inhibitor Libtayo (cemiplimab) for the treatment of cervical cancer and Teikoku Seiyaku’s tape formulation of donepezil for Alzheimer’s. Libtayo gained the nod to...read more